OTLK Swing-trade (and potential long-term growth) idea

NASDAQ:OTLK   Outlook Therapeutics, Inc.
OTLK (Outlook Therapeutics, Inc.) is expected to commercialize the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, Greater China and other markets. The stock recently spiked up in anticipation of the most recent earnings report, and experienced a brief pullback as "earnings/news" focused traders took profits. The base appears to have now consolidated, with the down trend now reversing into a positive uptrend with great potential as a swing-trade and long-term investment. (Just my opinion)

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.